Key result
Abrogation of CCR9 in mice significantly decreased myocardial infarct size (58.0% vs 75.9%) and improved left ventricular dysfunction by attenuating inflammation and apoptosis.
Why the study?
Does genetic abrogation of CCR9 improve post-MI cardiac remodeling and survival in mice?
Does genetic abrogation of CCR9 improve post-MI cardiac remodeling and survival in mice?
Abrogation of CCR9 ameliorates post-MI ventricular remodeling, inflammation, and apoptosis in mice, suggesting the CCR9-CCL25 axis as a potential therapeutic target for preventing heart failure after myocardial infarction.
CC chemokine receptor 9 (CCR9), which is a unique receptor for CC chemokine ligand (CCL25), is mainly expressed on lymphocytes, dendritic cells (DCs) and monocytes/macrophages. CCR9 mediates the chemotaxis of inflammatory cells and participates in the pathological progression of inflammatory diseases. However, the role of CCR9 in the pathological process of myocardial infarction (MI) remains unexplored; inflammation plays a key role in this process. Here, we used CCR9 knockout mice to determine the functional significance of CCR9 in regulating post-MI cardiac remodeling and its underlying mechanism. MI was induced by surgical ligation of the left anterior descending coronary artery in CCR9 knockout mice and their CCR9+/+ littermates. Our results showed that the CCR9 expression levels were up-regulated in the hearts of the MI mice. Abrogation of CCR9 improved the post-MI survival rate and left ventricular (LV) dysfunction and decreased the infarct size. In addition, the CCR9 knockout mice exhibited attenuated inflammation, apoptosis, structural and electrical remodeling compared with the CCR9+/+ MI mice. Mechanistically, CCR9 mainly regulated the pathological response by interfering with the NF-κB and MAPK signaling pathways. In conclusion, the data reveal that CCR9 serves as a novel modulator of pathological progression following MI through NF-κB and MAPK signaling.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2016) studied Myocardial infarction. CCR9 knockout vs. CCR9+/+ wild-type mice was evaluated on Infarct size at 24 hours post-MI (p=<0.05). Abrogation of CCR9 in mice significantly decreased myocardial infarct size (58.0% vs 75.9%) and improved left ventricular dysfunction by attenuating inflammation and apoptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: